BioSpace News Archive

Croda Pharma and BSI announced that they have entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical grade adjuvant QS-21, a potent component of adjuvant systems.

Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business.

NexImmune, Inc. (Nasdaq: NEXI) today announced that it will be presenting a poster at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, being held in Boston from June 20-23, 2023.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced the positive results from the Phase 2 CANAL trial in adults with IPF chronic cough has been published in NEJM Evidence.

Nordson Corporation reported results for the fiscal second quarter ended April 30, 2023. Sales were $650 million, a 2% increase compared to the prior year’s second quarter sales of $635 million.

Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced that it will host a conference call to discuss fiscal 2023 third quarter financial results.

Novanta Inc. announced that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at Baird’s 2023 Global Consumer, Technology & Services Conference on Wednesday, June 7, 2023, in New York, NY.

Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.

Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.